Health Care [ 9/12 ] | Biotechnology [ 44/73 ]
NASDAQ | Common Stock
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.
SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.43 M Decreased by -292.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.67 M Decreased by -306.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.26 M Decreased by -424.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -19.21 M Decreased by -1.64 K% | Decreased by N/A% - |
| Sep 30, 22 | 0.00 Decreased by N/A% | -1.89 M Decreased by -77.65% | Decreased by N/A% - |
| Jun 30, 22 | 0.00 - | -902.00 K - | Decreased by N/A% - |
| Mar 31, 22 | 0.00 - | -1.00 M - | Decreased by N/A% - |
| Jun 30, 21 | N/A - | -1.11 M - | - - |